Experimental study on treatment of bladder cancer with a combination of TRAIL and chemotherapeutic agents

Objective To explore the role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and the effect of TRAIL combined with chemotherapeutic agents in treatment of bladder cancer.Methods T24 and 5637 bladder cancer cell lines were employed in our study.100μl of target cell suspension were added to each well of 96-well plates.The bladder cancer cells were incubated for 24 hours with TRAIL,Adriamycin,MitomycinC and TRAIL combined with chemotherapeutic agents at different concentration。MTT working solution was added to each culture well and calculated the survival rates of bladder cancer cells.Bladder cancer cell suspension was added to 12-well plates,then incubated for 12 hours with TRAIL,Adriamycin,Mitomycin and TRAIL combined with chemotherapeutic agents at different concentration.The rates of apoptosis and death of bladder cancer cells were detected by flow cytometry.Results The rates of apoptosis of bladder cancer cell T24、5637 were 20.1%、47.5% by treated with 100 μg/l TRAIL singly,which had significant difference compared with the groups without agents(P0.01);The inhibitory rates of T24、5637 were 36.0%、44.1%、26.7%、30.2% by treated with 10 mg/L MMC、ADM.However the inhibitory rates reached 58.4%、73.7%、90.7%、88.2% by 100 μg/l TRAIL combined with 10 mg/L MMC、ADM in T24 and 5637.Combinations of TRAIL and MMC,TRAIL and ADM resulted in a synergistic cytotoxic effect (P0.05).Conclusions In vitro,TRAIL is an agent for anti-bladder cancer by inducing the apoptosis of tumor cell ;TRAIL can enhance the effect of Adriamycin and Mitomycin C.